Poster: 3D cell culture taking into account the extracellular matrix for phenotypic screening in the frame of Parkinson’s disease (SLAS Building Biology in 3D symposium)

Poster presented during the SLAS Building Biology in 3D symposium event in Cambridge on April, 21th 2023. Title: 3D cell culture taking into account the extracellular matrix for phenotypic screening in the frame of Parkinson’s disease V. De Conto 1*, Cheung V.1, Alejandra Mogrovejo – Valdivia1, Maubon N.1, Vandenhaute E.1, Read more…

Poster: An Extracellular Matrix-like hydroscaffold for 3D cell culture to bring the gap between in vitro & in vivo: focus on cancer models (SLAS Building Biology in 3D symposium)

Poster presented during the SLAS Building Biology in 3D symposium event in Cambridge on April, 20th 2023. Title: 3D cell culture taking into account the extracellular matrix for bridging the gap between in vitro & in vivo: focus on cancer models V. De Conto 1 *, M. Fernandes2, J. Cicero, Read more…

Animal tests no longer necessary before drug clinical trials? Let’s make it in 3D in preclinical studies… and with the extracellular matrix!

End of last year, the american legislation has ratified that new drugs no longer need to be tested in animals to receive Food and Drug Administration (FDA) approval. This is a huge step toward animal-free validation of drugs, but it requires the design of a relevant and more predictive drug Read more…

Presentation of BIOMIMESYS technology, the first organ-specific in vitro ECM, to develop innovative and predictive 3D cellular models for drug discovery – Academia Sinica, the 1st of November 2022

BIOMIMESYS® is a patented 3D matrix reproducing the physicochemical properties of the extracellular matrix (ECM), different from classical hydrogels used for 3D cell culture. It is composed of native ECM components: Hyaluronic Acid (HA) combined with collagens, adhesion peptides… in the form of a unique hydroscaffold, i.e. exhibiting a dual Read more…

Poster (OncoLilleDays2022) – Mechanobiological characterization of a 3D in vitro pancreatic ductal adenocarcinoma model and the study of tumor-stroma interaction

Thomas Meynard, PhD student in OncoLille (under the supervision of Vincent Senez and Isabelle Van Seuningen) in collaboration with HCS Pharma too, presented a poster showing that it is possible to include BIOMIMESYS® in a microfluidic chip to co-culture Cancer-Associated fibroblasts and cancerous cells, with the aim to increase the Read more…

Poster – Including the matricial tumoral microenvironment in 3D in vitro models by using a Hyaluronic-Acid-based hydroscaffold™

Abstract: In oncology, 97% of drug candidates fail in clinical trials. This highlights a lack of relevance of preclinical models used upstream. Indeed, human in vitro models don’t consider the Tumoral Extracellular Matrix (TECM). However, more and more studies demonstrate that ECM composition and stiffness are modified in tumors and Read more…

Importance du microenvironnement dans les modèles cérébraux in vitro pour le criblage phénotypique

Presentation in english Environ 90 % des candidats médicaments échouent aux essais cliniques, notamment en neurologie, faute d’efficacité. Cela met en évidence un manque de pertinence dans les modèles précliniques, y compris les modèles in vitro, qui ne prennent pas en compte le microenvironnement, composé par les cellules gliales et Read more…

Poster – (ECM 2022) Development of innovative hiPSC-based model including an innovative 3D modified hyaluronic acid hydroscaffold for phenotypic screening

We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to studymetabolic diseases upon hepatocyte-like cell (HLC) differentiation. With a non-invasive approach, hiPSCs can be generated from urine samples of patients and HLCs have been used to model cholesterol metabolism regulation, by the study of LDLR- and Read more…